作者: C. Kalka , H. Masuda , T. Takahashi , W. M. Kalka-Moll , M. Silver
关键词:
摘要: Animal studies and preliminary results in humans suggest that lower extremity myocardial ischemia can be attenuated by treatment with angiogenic cytokines. The resident population of endothelial cells is competent to respond an available level growth factors, however, may potentially limit the extent which cytokine supplementation enhances tissue neovascularization. Accordingly, we transplanted human progenitor (hEPCs) athymic nude mice hindlimb ischemia. Blood flow recovery capillary density ischemic were markedly improved, rate limb loss was significantly reduced. Ex vivo expanded hEPCs thus have utility as a “supply-side” strategy for therapeutic